Leishmaniasis: Challenges in the control and eradication

Challenges in Infectious Diseases

Volumn , Issue , 2013, Pages 247-264

  Sundar, Shyam ^a   Chakravarty, Jaya ^a  

^a BANARAS HINDU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84918572812     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4496-1_8     Document Type: Chapter

References (75)

1. Pearson RD, Sousa AQ (1996) Clinical spectrum of leishmaniasis. Clin Infect Dis 22:1-13
2. Sundar S (2012) Leishmaniases. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (eds) Harrisons's Priniciples of Internal Medicine, 18th edn. McGraw Hill, New York, pp 1709-1716
3. Control of the Leishmaniasis. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22-26 Mar 2010. http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf. Accessed on 29 May 2011
4. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, Alvar J, Boelaert M (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5:873-882
5. Pearson RD, Jeronimo SMB, de Queiroz Sousa A (1999) Leishmaniasis. In: Guerrant RL, Walker DH, Weller PF (eds) Tropical infectious diseases: principles, pathogens and practice. Churchill Livingstone, Philadelphia, pp 797-813
6. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM (2003) Post-kala-azar dermal leishmaniasis. Lancet Infect Dis 3:87-98
7. Thakur CP, Kumar K (1992) Post kala-azar dermal leishmaniasis: a neglected aspect of kalaazar control programmes. Ann Trop Med Parasitol 86:355-359
8. Seaman J, Mercer AJ, Sondorp E (1996) The epidemic of visceral leishmaniasis in western Upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol 25:862-871
9. Alvar J, Canavate C, Gutierrez-Solar B, Jimenez M, Laguna F, Lopez-Velez R, Molina R, Moreno J (1997) Leishmania and human immunode ficiency virus coinfection: the first 10 years. Clin Microbiol Rev 10:298-319
10. Olivier M, Badaro R, Medrano FJ, Moreno J (2003) The pathogenesis of Leishmania/HIV coinfection: cellular and immunological mechanisms. Ann Trop Med Parasitol 97:79-98
11. Tremblay M, Olivier M, Bernier R (1996) Leishmania and the pathogenesis of HIV infection. Parasitol Today 12:257-261
12. Gradoni L, Scalone A, Gramiccia M, Troiani M (1996) Epidemiological surveillance of leishmaniasis in HIV-1-infected individuals in Italy. AIDS 10:785-791
13. Lopez-Velez R, Perez-Molina JA, Guerrero A, Baquero F, Villarrubia J, Escribano L, Bellas C, Perez-Corral F, Alvar J (1998) Clinicoepidemiologic characteristics, prognostic factors, and survival analysis of patients coinfected with human immunode ficiency virus and Leishmania in an area of Madrid, Spain. Am J Trop Med Hyg 58:436-443
14. Pintado V, Martin-Rabadan P, Rivera ML, Moreno S, Bouza E (2001) Visceral leishmaniasis in human immunode ficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore) 80:54-73
15. Rosenthal E, Marty P, Poizot-Martin I, Reynes J, Pratlong F, Lafeuillade A, Jaubert D, Boulat O, Dereure J, Gambarelli F, Gastaut JA, Dujardin P, Dellamonica P, Cassuto JP (1995) Visceral leishmaniasis and HIV-1 co-infection in southern France. Trans R Soc Trop Med Hyg 89:159-162
16. Laguna F, Videla S, Jiménez-Mejías ME, Sirera G, Torre-Cisneros J, Ribera E, Prados D, Clotet B, Sust M, López-Vélez R, Alvar J, Spanish HIV-Leishmania Study Group (2003) Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study. J Antimicrob Chemother 52:464-468
17. Alvar J, Gutiérrez-Solar B, Pachón I, Calbacho E, Ramírez M, Vallés R et al (1996) AIDS and Leishmania infantum. New approaches for a new epidemiological problem. Clin Dermatol 14:541-546
18. Molina R, Gradoni L, Alvar J (2003) HIV and the transmission of Leishmania. Ann Trop Med Parasitol 97:29-45
19. Desjeux P, Alvar J (2003) LeishmaniaIHIV co-infections: epidemiology in Europe. Ann Trop Med Parasitol 97:3-15
20. Alvar J, Aparicio P, Aseffa A, Den Boer M, Cañavate C, Dedet JP, Gradoni L, Ter Horst R, López-Vélez R, Moreno J (2008) The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 21:334-359
21. Rijal S, Boelaert M, Regmi S, Karki BM, Jacquet D, Singh R, Chance ML, Chappuis F, Hommel M, Desjeux P, Van der Stuyft P, Le Ray D, Koirala S (2004) Evaluation of a urinary antigen-based latex agglutination test in the diagnosis of kala-azar in eastern Nepal. Trop Med Int Health 9:724-729
22. Sundar S, Singh RK, Bimal SK, Gidwani K, Mishra A, Maurya R, Singh SK, Manandhar KD, Boelaert M, Rai M (2007) Comparative evaluation of parasitology and serological tests in the diagnosis of visceral leishmaniasis in India: a phase III diagnostic accuracy study. Trop Med Int Health 12:284-289
23. Sundar S, Agrawal S, Pai K, Chance M, Hommel M (2005) Detection of leishmanial antigen in the urine of patients with visceral leishmaniasis by a latex agglutination test. Am J Trop Med Hyg 73:269-271
24. Chappuis F, Rijal S, Soto A, Menten J, Boelaert M (2006) A meta-analysis of the diagnostic performance of the direct agglutination test and rK39 dipstick for visceral leishmaniasis. BMJ 333:723
25. De Almeida SL, Romero HD, Prata A, Costa RT, Nascimento E, Carvalho SF, Rodrigues V (2006) Immunologic tests in patients after clinical cure of visceral leishmaniasis. Am J Trop Med Hyg 75:739-743
26. Hailu A (1990) Pre- and post-treatment antibody levels in visceral leishmaniasis. Trans R Soc Trop Med Hyg 84:673-675
27. Koirala S, Karki P, Das ML, Parija SC, Karki BM (2004) Epidemiological study of kala-azar by direct agglutination test in two rural communities of eastern Nepal. Trop Med Int Health 9:533-537
28. Schenkel K, Rijal S, Koirala S, Koirala S, Vanlerberghe V, Van der Stuyft P, Gramiccia M, Boelaert M (2006) Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors. Trop Med Int Health 11:1792-1799
29. Schaefer KU, Kurtzhals JA, Gachihi GS, Muller AS, Kager PA (1995) A prospective seroepidemiological study of visceral leishmaniasis in Baringo District, Rift Valley Province, Kenya. Trans R Soc Trop Med Hyg 89:471-475
30. Sundar S, Singh RK, Maurya R, Kumar B, Chhabra A, Singh V, Rai M (2006) Serological diagnosis of Indian visceral leishmaniasis: direct agglutination test versus rK39 strip test. Trans R Soc Trop Med Hyg 100:533-537
31. Sundar S, Maurya R, Singh RK, Bharti K, Chakravarty J, Parekh A, Rai M, Kumar K, Murray HW (2006) Rapid, noninvasive diagnosis of visceral leishmaniasis in India: comparison of two immunochromatographic strip tests for detection of anti-K39 antibody. J Clin Microbiol 44:251-253
32. Ibrahim ME, Lambson B, Yousif AO, Deifalla NS, Alnaiem DA, Ismail A, Yousif H, Ghalib HW, Khalil EA, Kadaro A, Barker DC, El Hassan AM (1999) Kala-azar in a high transmission focus: an ethnic and geographic dimension. Am J Trop Med Hyg 61:941-944
33. Burns JM Jr, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG (1993) Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects speci fic antibody in African and American visceral leishmaniasis. Proc Natl Acad Sci U S A 90:775-779
34. Ritmeijer K, Melaku Y, Mueller M, Kipngetich S, O'keeffe C, Davidson RN (2006) Evaluation of a new recombinant K39 rapid diagnostic test for Sudanese visceral leishmaniasis. Am J Trop Med Hyg 74:76-80
35. Veeken H, Ritmeijer K, Seaman J, Davidson R (2003) Comparison of an rK39 dipstick rapid test with direct agglutination test and splenic aspiration for the diagnosis of kala-azar in Sudan. Trop Med Int Health 8:164-167
36. Diro E, Techane Y, Tefera T, Assefa Y, Kebede T, Genetu A, Kebede Y, Tesfaye A, Ergicho B, Gebre-Yohannes A, Mengistu G, Engers H, Aseffa A, Desjeux P, Boelaert M, Hailu A (2007) Field evaluation of FD-DAT, rk-39 dipstick and KATEX (urine latex agglutination) for diagnosis of visceral leishmaniasis in northwest Ethiopia. Trans R Soc Trop Med Hyg 101:908-914
37. Boelaert M, El-Safi S, Hailu A, Mukhtar M, Rijal S, Sundar S, Wasunna M, Aseffa A, Mbui J, Menten J, Desjeux P, Peeling RW (2008) Diagnostic tests for kala-azar: a multi-centre study of the freeze-dried DAT, rK39 strip test and KAtex in East-Africa and the Indian subcontinent. Trans R Soc Trop Med Hyg 102:32-40
38. Faber WR, Oskam L, van Gool T, Kroon NC, Knegt-Junk KJ, Hofwegen H, van der Wal AC, Kager PA (2003) Value of diagnostic techniques for cutaneous leishmaniasis. J Am Acad Dermatol 49:70
39. Medeiros AC, Rodrigues SS, Roselino AM (2002) Comparison of the speci ficity of PCR and the histopathological detection of leishmania for the diagnosis of American cutaneous leishmaniasis. Braz J Med Biol Res 35(4):421
40. Weigle KA, Labrada LA, Lozano C, Santrich C, Barker DC (2002) PCR-based diagnosis of acute and chronic cutaneous leishmaniasis caused by Leishmania (Viannia). J Clin Microbiol 40(2):601-606
41. Sundar S, More DK, Singh MK, Singh VP, Sharma S, Makharia A, Kumar PC, Murray HW (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31:1104-1107
42. Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BM, Das ML, Desjeux P, Loutan L, Koirala S (2003) Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 97:350-354
43. Sundar S, Thakur BB, Tandon AK, Agrawal NR, Mishra CP, Mahapatra TM, Singh VP (1994) Clinico-epidemiological study of drug resistance in Indian kala-azar. BMJ 308:307
44. Sundar S, Sinha PR, Agrawal NK, Srivastava R, Rainey PM, Berman JD, Murray HW, Singh VP (1998) A cluster of severe antimony cardiotoxicity in kala-azar due to high osmolality lot. Am J Trop Med Hyg 59:139-143
45. Thakur CP, Singh RK, Hassan SM, Kumar R, Narain S, Kumar A (1999) Amphotericin B deoxycholate treatment of visceral leishmaniasis with newer modes of administration and precautions: a study of 938 cases. Trans R Soc Trop Med Hyg 93:9-23
46. Mishra M, Biswas UK, Jha DN, Khan AB (1992) Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 340:1256-1257
47. Olliaro P, Sundar S (2009) Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop Med Int Health 14:88-92
48. Sundar S, Chakravarty J, Agarwal D, Rai M, Murray HW (2010) Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med 362:504-512
49. Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347:1739-1746
50. Sundar S, Murray HW (2005) Availability of miltefosine for the treatment of kala-azar in India. Bull World Health Organ 83:394-395
51. Bhattacharya SK, Sinha PK, Sundar S, Thakur CP, Jha TK, Pandey K, Das VR, Kumar N, Lal C, Verma N, Singh VP, Ranjan A, Verma RB, Anders G, Sindermann H, Ganguly NK (2007) Phase IV trial of miltefosine in the treatment of Indian visceral leishmaniasis. J Infect Dis 196:591-598
52. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK (2007) Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356:2571-2581
53. Sundar S, Rai M (2005) Treatment of visceral leishmaniasis. Expert Opin Pharmacother 6:2821-2829
54. Sundar S, Rai M, Chakravarty J, Agarwal D, Agrawal N, Vaillant M, Olliaro P, Murray HW (2008) New treatment approach in indian visceral leishmaniasis: single-dose liposomal amphotericin b followed by short-course oral miltefosine. Clin Infect Dis 47:1000-1006
55. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, Alam S, Chakravarty J, Vaillant M, Verma N, Pandey K, Kumari P, Lal CS, Arora R, Sharma B, Ellis S, Strub-Wourgaft N, Balasegaram M, Olliaro P, Das P, Modabber F (2011) Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 377:477-486
56. Ritmeijer K, Dejenie A, Assefa Y, Hundie TB, Mesure J, Boots G, den Boer M, Davidson RN (2006) A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 43:357-364
57. Nadim A, Javadian E, Tahvildar-Bidruni G, Ghorbani M (1983) Effectiveness of leishmanization in the control of cutaneous leishmaniasis. Bull Soc Pathol Exot Filiales 76:377-383
58. Greenblatt CL (1988) Cutaneous leishmaniasis: the prospects for a killed vaccine. Parasitol Today 4:53-54
59. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, Ibrahim ME, Kamil AA, Elsheikh M, Babiker A, Modabber F (2000) Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet 356:1565-1569
60. Musa AM, Khalil EAG, Ismail A, Elhassan IM, Fesharki H, Khamesipour A, Modabber F, Zijlstra EE, El-Hassan AM (2005) Safety, immunogenicity and possible efficacy of immunochemotherapy of persistent post kala-azar dermal leishmaniasis. Sudan J Dermatol 3:63-72
61. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, Webb JR, Campos-Neto A, Reed SG (2002) Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 20:3292-3303
62. Reed SG, Coler RN, Campos-Neto A (2003) Development of a leishmaniasis vaccine: the importance of MPL. Expert Rev Vac 2:239-252
63. Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Pine SO, Cowgill KD, Reed SG, Piazza FM (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis. Vaccine 28(40):6581-6587
64. Llanos-Cuentas A, Calderón W, Cruz M, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Bertholet S, Laughlin EM, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Piazza FM (2010) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 28(46):7427-7435
65. Chakravarty J, Kumar S, Trivedi S, Rai VK, Singh A, Ashman JA, Laughlin EM, Coler RN, Kahn SJ, Beckmann AM, Cowgill KD, Reed SG, Sundar S, Piazza FM (2011) A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1 + MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine 29(19):3531-3537
66. Alvar J, Molina R, San Andrés M, Tesouro M, Nieto J, Vitutia M, González F, San Andrés MD, Boggio J, Rodriguez F (1994) Canine leishmaniasis: clinical, parasitological and entomological follow-up after chemotherapy. Ann Trop Med Parasitol 88:371-378
67. Gavgani AS, Hodjati MH, Mohite H, Davies CR (2002) Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet 360:374-379
68. Kaul SM, Sharma RS, Dey KP, Rai RN, Verghese T (1994) Impact of DDT indoor residual spraying on Phlebotomus argentipes in a kala-azar endemic village in eastern Uttar Pradesh. Bull World Health Organ 72:79-81
69. Hassan MM, Elraba'a FM, Ward RD, Maingon RD, Elnaiem DA (2004) Detection of high rates of in-village transmission of Leishmania donovani in eastern Sudan. Acta Trop 92:77-82
70. Bern C, Hightower AW, Chowdhury R, Ali M, Amann J, Wagatsuma Y, Haque R, Kurkjian K, Vaz LE, Begum M, Akter T, Cetre-Sossah CB, Ahluwalia IB, Dotson E, Secor WE, Breiman RF, Maguire JH (2005) Risk factors for kala-azar in Bangladesh. Emerg Infect Dis 11:655-662
71. Bern C, Joshi AB, Jha SN, Das ML, Hightower A, Thakur GD, Bista MB (2000) Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg 63:184-188
72. Picado A, Singh SP, Rijal S, Sundar S, Ostyn B, Chappuis F, Uranw S, Gidwani K, Khanal B, Rai M, Paudel IS, Das ML, Kumar R, Srivastava P, Dujardin JC, Vanlerberghe V, Andersen EW, Davies CR, Boelaert M (2010) Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ 341:c6760. doi: 10.1136/bmj.c6760
73. Ritmeijer K, Davies C, van Zorge R, Wang SJ, Schorscher J, Dongu'du SI, Davidson RN (2007) Evaluation of a mass distribution programme for fine-mesh impregnated bednets against visceral leishmaniasis in eastern Sudan. Trop Med Int Health 12:404-414
74. Singh SP, Hasker E, Picado A, Gidwani K, Malaviya P, Singh RP, Boelaert M, Sundar S (2010) Risk factors for visceral leishmaniasis in India: further evidence on the role of domestic animals. Trop Med Int Health 15:29-35
75. Hotez PJ, Remme JH, Buss P, Alleyne G, Morel C, Breman JG (2004) Combating tropical infectious diseases: report of the Disease Control Priorities in Developing Countries Project. Clin Infect Dis 38:871-878